Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells
Authors:
Open Access
- 10 November 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy in adults and accounts for 85–90% of all primary liver cancer. Based on the estimation by the International Agency for Research on Cancer in 2018, liver cancer is the fourth leading cause of cancer death globally. Dihydroartemisinin (DHA), the main active metabolite of artemisinin derivatives, is a well-known drug for the treatment of malaria. Previous studies have demonstrated that DHA exhibits antitumor effects toward a variety of human cancers and has a potential for repurposing as an anticancer drug. However, its short half-life is a concern and may limit the application in cancer therapy. We have reported that UDC-DHA, a hybrid of bile acid ursodeoxycholic acid (UDCA) and DHA, is ∼12 times more potent than DHA against a HCC cell line HepG2. In this study, we found that UDC-DHA was also effective against another HCC cell line Huh-7 with an IC50 of 2.16 μM, which was 18.5-fold better than DHA with an IC50 of 39.96 μM. UDC-DHA was much more potent than the combination of DHA and UDCA at 1:1 molar ratio, suggesting that the covalent linkage rather than a synergism between UDCA and DHA is critical for enhancing DHA potency in HepG2 cells. Importantly, UDC-DHA was much less toxic to normal cells than DHA. UDC-DHA induced G0/G1 arrest and apoptosis. Both DHA and UDC-DHA significantly elevated cellular reactive oxygen species generation but with different magnitude and timing in HepG2 cells; whereas only DHA but not UDC-DHA induced reactive oxygen species in Huh-7 cells. Depolarization of mitochondrial membrane potential was detected in both HepG2 and Huh-7 cells and may contribute to the anticancer effect of DHA and UDC-DHA. Furthermore, UDC-DHA was much more stable than DHA based on activity assays and high performance liquid chromatography-MS/MS analysis. In conclusion, UDC-DHA and DHA may exert anticancer actions via similar mechanisms but a much lower concentration of UDC-DHA was required, which could be attributed to a better stability of UDC-DHA. Thus, UDC-DHA could be a better drug candidate than DHA against HCC and further investigation is warranted.Keywords
Funding Information
- Ministry of Science and Technology (MOST 108-2320-B-002-057, MOST 109-2320-B-002-048)
This publication has 41 references indexed in Scilit:
- Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cellsApoptosis, 2015
- Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone estersEuropean Journal of Medicinal Chemistry, 2015
- Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitroInternational Journal of Molecular Medicine, 2012
- Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivoBiochemical Pharmacology, 2012
- The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in CancerAnnual Review of Pharmacology and Toxicology, 2012
- Dihydroartemisinin induces autophagy and inhibits the growth of iron‐loaded human myeloid leukemia K562 cells via ROS toxicityFEBS Open Bio, 2012
- The discovery of artemisinin (qinghaosu) and gifts from Chinese medicineNature Medicine, 2011
- The pharmaceutical death-ride of dihydroartemisininMalaria Journal, 2010
- Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of ActionClinical Cancer Research, 2008
- Novel cytotoxic agents from an unexpected source: Bile acids and ovarian tumor apoptosisGynecologic Oncology, 2007